Menu

Building the next generation of healthcare companies

Delivering transformational treatments to patients Generating superior returns for shareholders

Who we are

Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Investors

Syncona is a FTSE250 business listed on the London Stock Exchange. Find the latest share price, announcements, presentations and events here.

Our portfolio

A selective portfolio of high quality healthcare businesses in truly innovative areas of science

Learn more

Transformational treatments

As we seek to build companies in truly innovative areas in healthcare, our ultimate goal is to deliver transformational treatments to patients, enabling them to continue enjoying their lives

Learn more

Achilles Therapeutics and the advent of immunotherapy

Syncona speaks to Achilles Therapeutics' clinical founder Charlie Swanton about his career, the advent of immunotherapy, and what he wants Achilles to achieve.

Emma Salisbury - measuring the potential impact of gene therapy

Emma Salisbury, mother of Tommy Salisbury, tells us about the impact of Choroideremia and the potential of gene therapy.

Latest news

View all
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
13.02.2019
View
Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer
12.02.2019
View
First production and administration of Axumin® (fluciclovine (18F)) in Italy.
12.02.2019
View
Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer (5)
07.02.2019
View